GLP-1 Receptor Agonist Market, By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Albiglutide, Semaglutide), By Route of Administration (Parenteral and Oral), By Application (Type 2 Diabetes Mellitus, Obesity, Liver Cirrhosis, Non-alcoholic

GLP-1 receptor agonists are an important class of anti-diabetic drugs for the treatment of type 2 diabetes. These mimic the effects of endogenous glucagon-like peptide-1 (GLP-1), a peptide hormone released after eating which stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner. By binding to and activating the GLP-1 receptor, these drugs induce insulin secretion, inhibit glucagon release, suppress appetite and promote weight loss in diabetic patients. Their superior glucose control efficacy and low risk of hypoglycemia as compared to other classes make them an attractive option, thus, driving the market growth.

Market Dynamics:

Global GLP-1 receptor agonist market growth is driven by growing prevalence of diabetes worldwide coupled with the superior therapeutic efficacy of GLP-1 receptor agonists. Rising levels of obesity can increase the risk of type 2 diabetes, thus, boosting demand for more effective medical treatments. However, high development costs and stringent regulatory approvals can hamper the market growth. New product launches featuring improved formulations, flexible dosing options, longer duration of action and multi-indication usage can offer growth opportunities. Manufacturers are investing in R&D to expand clinical indications and develop oral versions of these drugs to improve patient convenience.

Key Features of the Study:

• This report provides in-depth analysis of the global GLP-1 receptor agonist market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global GLP-1 receptor agonist market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company and Sanofi
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global GLP-1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GLP-1 receptor agonist market

• By Drug Class
• Exenatide
• Liraglutide
• Dulaglutide
• Lixisenatide
• Albiglutide
• Semaglutide
• By Route of Administration
• Parenteral
• Oral
• By Application
• Type 2 Diabetes Mellitus
• Obesity
• Liver Cirrhosis
• Non-alcoholic Steatohepatitis
• Others
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Eli Lilly and Company
• Sanofi
• Novo Nordisk A/S
• AstraZeneca
• Perrigo Company PLC
• 3M Company
• Bausch Health
• Taro Pharmaceutical Industries
• Novan Inc.
• Serum Institute of India Pvt. Ltd.
• Orgenesis biotech company
• Verrica Pharmaceuticals
• AbbVie Inc.
• Lee's Pharmaceutical Holdings Ltd
• Cassiopea
• Glenmark Pharmaceuticals
• Cassiopea